River blindness drug trial aims to find right dose for kids

NCT ID NCT03962062

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a single dose of moxidectin in 36 children aged 4 to 17 who have or are at risk of onchocerciasis (river blindness). The goal was to find a dose for children 4-11 years that works like the standard 8 mg dose used in older kids and adults. Researchers measured drug levels in the blood and checked for side effects to ensure safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

moxidectin (a tablet taken by mouth)

What this could lead to

If successful, this could help determine a safe and effective dose of moxidectin for children aged 4-11 with onchocerciasis, potentially improving treatment access for younger patients.

What could go wrong

This is a small, early-phase study with only 36 participants, so results may not apply broadly. The trial focuses on drug levels and safety, not on curing the disease, and side effects are possible.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ONCHOCERCIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

onchocerciasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Health and Allied Services School of Public Health

    Hohoe, Volta Region, Ghana